News Image

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

Provided By PR Newswire

Last update: Aug 14, 2024

— Improved loss from operations by 81% —

— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections 

Read more at prnewswire.com

ADITXT INC

NASDAQ:ADTX (7/23/2025, 8:01:21 PM)

After market: 1.2107 -0.02 (-1.57%)

1.23

-0.01 (-0.81%)



Find more stocks in the Stock Screener

Follow ChartMill for more